Introduction
A major goal of cancer gene therapy is to be able to deliver specifically therapeutic genes to target tumors. To achieve this goal, several viral and non-viral gene therapy vector systems have been developed. One major advantage of viral vectors over non-viral vectors is their higher transduction efficiency. However, compared with non-viral vector systems, viral vectors are more likely to raise concerns about potential deleterious effects associated with the parental viruses, especially for vectors derived from known human pathogens. For this reason, several strategies have been developed to reduce the likelihood of vector toxicities associated with the parental virus. The most common approach involves partial deletion of viral genomes that are required for viral replication (replication-defective), or alternatively, conditioning the vector's replication to certain cellular parameters (conditional replication), such as the expression of the Ras oncogene.
Our research group has focused on the development of replication-defective Sindbis viral vectors for cancer gene therapy, because these have a number of positive attributes. First, the genome of Sindbis virus is a sense, single-stranded RNA virus and there is no DNA phase in its life cycle, precluding risks associated with genomic integration. 1 Second, with a relatively small genome (B12 kbp), the vector system can be easily modified to express different therapeutic genes. 2, 3 Third, the vector is capable of systemic dissemination throughout the body via the bloodstream. 4 The latter property makes Sindbis vectors among the few that have the capability of systemic tumor targeting. Fourth, the vector targets cancer cells via the 67-kDa high-affinity laminin receptor (LAMR), 5, 6 which is substantially upregulated and associated with invasiveness in numerous human cancers. 7 A significant number of LAMRs on tumor cells appear not to be occupied by laminin, and hence available for Sindbis vector binding. By contrast, unoccupied receptors are likely to be scarce on normal cells, providing a means for differential targeting of tumors versus normal cells 8, 9 and also limiting permissive transduction of most normal cells.
Taking advantage of these special features, we have demonstrated specific tumor targeting of Sindbis vectors in several in vivo tumor models. 10, 11 Consecutive vector treatments are safe and have shown no morbidity and mortality in our experimental tumor models. Several additional factors may contribute to the safety of the vector system. First, in comparison with other oncolytic vectors, Sindbis vectors cause tumor apoptosis after transduction instead of lysis and necrosis that are more inflammatory to surrounding normal tissues. 12, 13 Second, transduction of most healthy adults by the wild-type, replication-competent Sindbis virus typically causes no symptomology or may cause mild self-limited symptoms such as rash, arthralgia and moderate fever that are not life threatening to human. 4 Even so, we currently use replication-defective Sindbis vectors to enhance safety in our tumor models. 14 The fact that minimal, if any, adverse effects are observed contrasts with the strong anti-tumor results observed in several of our cancer models and suggest an inherent difference in vivo between tumor cells and normal cells in sensitivity to Sindbis vector transduction. One such difference, as discussed above, is the availability of LAMRs in tumor and normal cells.
To determine further the potential of replication defective Sindbis vectors for in vivo therapy, we examined some potential host responses that might limit vector use. The innate immune responses of the host, involving cytokines such as IFNs, might be expected to play important roles in the safety of Sindbis vectors but also pose limitations to their use. In particular, IFN-I and JAK-STAT signaling pathways are known to establish an 'alarming' state that suppresses replication and propagation of several viruses during the early stage of infection. 15 IFN-Is, such as IFN-a and IFN-b, are important anti-viral cytokines and serve as the first line of innate immunity against viral infection. Both IFN-a/b share the same cellular receptor (IFNAR); binding activates a signaling cascade that is mediated by the Janus kinase/signal transducer and activator of transcription (STAT) pathway. 15 IFNAR activation triggers the downstream Janus kinase (JAK)-mediated tyrosine phosphorylation of STAT1 and STAT2. Phosphorylated STAT1 and STAT2 molecules form heterodimers and translocate to the nucleus in association with another transcription factor, interferon regulatory factor 9 (IRF9). This trimolecular complex (STAT1-STAT2-IRF9), named interferon-stimulated gene factor 3 (ISGF3), binds to a specific DNA recognition element, interferon-stimulated response element, to modulate the transcription of a large number of genes that contribute to the antiviral function of these cytokines.
Unlike replication-defective vectors, replication-competent wild-type Sindbis virus has been shown to infect macrophage-dendritic cell-like cells in the draining lymph nodes causing viremia within 24 h in mice lacking functional receptors for IFN-a/b. In IFNAR-deficient mice the virus results in widespread infection of monocyte-lineage cells throughout the body and mortality at later stages (472 h) of infection, while wild-type mice experience no morbidity or mortality. 16 However, the toxicity of replication-defective Sindbis vector in mice lacking a functional IFN-I signaling pathway has not been addressed. One of the challenges of such a study is that of measuring early vector delivery and transduction. Since the vector is replication defective, traditional plaque assays that require longer time (418 h) for viral propagation are not feasible. To overcome this limitation, one can use in vivo bioluminescent imaging methods to detect the early transduction of the replication-defective vector, as measured by expression of a reporter transgene, such as luciferase. Non-invasive bioluminescent imaging does not require viral propagation for analysis and therefore enable us to observe the early stages of vector transduction, before the onset of viremia usually occurs in mice treated with replicationcompetent wild-type virus. We have used this method to examine vector transduction in wild-type mice and in mice lacking functional IFN-I/STAT1 signaling. Replication-defective Sindbis/Fluc vector was produced using the defective helper DHBB and a SinRep5 replicon, 14 which carries a firefly luciferase gene for bioluminescent IVIS imaging. 2 The vector treatment resulted in extensive transduction of IFN-a/bR À/À mice in the upper region of the abdomen 24 h after vector injection ( Figure 1a, day 1) . In some cases, minor transduction was also observed in the lower region of the abdomen (Figure 1a , yellow arrow). By contrast, the vector caused no detectable permissive transduction in background 129 Sv/Ev mice. By imaging individual organs, we confirmed that the stronger signal is clearly associated with the liver of IFN-a/bR À/À mice (Figure 1b) , and the weaker signals correspond to the peritoneal fat of IFN-a/bR À/À animals. No signal is present in the stomach, spleen, pancreas, bowel, heart, lung, thymus and kidney in either knockout or wild-type mice. Interestingly, an additional Sindbis/Fluc treatment on day 2 did not lead to detectable re-transduction of the liver on day 3 ( Figure 1a ) and subsequently all treated animals remained signal-free. No observable morbidity or mortality in IFN-a/bR À/À animals was associated with these systemic Sindbis/Fluc treatments. These results suggest that in the absence of IFN-I responses, Sindbis vector initially transduces some liver cells, but this transduction appears to resolve within 3 days. It is surmized that in wild-type mice, IFN-I responses are involved in suppressing Sindbis vectors for permissive transduction.
Results and discussion
To determine if STAT1, a downstream mediator of IFN-I signaling, is involved in the anti-Sindbis effects in the liver, similar experiments were performed in mice lacking STAT1. Transduction of some liver cells was observed only on day 1 but not subsequently, which is consistent with observations in IFN-a/bR À/À mice ( Figure 1c ). One explanation for these findings might be that after the first injection, adaptive immunity rather than IFN-I innate immunity is involved in liver protection. To test this notion, we performed the same experiment using SCID and Stat1 
/Rag2
À/À double knockout mice as in Stat1 À/À mice. Thus, the absence of persistent liver transduction in SCID and Stat1
À/À mice ( Figure 1c) is not likely the result of adaptive immunity, since mice lacking RAG2, which is required for generation of T and B cells, and STAT1 show the same transduction pattern as STAT1 KO mice; that is, transduction after the initial inoculum, but not transduction after subsequent injections. As Sindbis transduction is transient because no integration of the viral genome occurs, and the vectors used are replication defective, no super-transduction block appears likely.
In addition to IFN-a/b signaling, STAT1 also participates in the IFN-g signaling, a type II interferon pathway in which IFN-g signaling utilizes phosphorylated STAT1 homodimer (STAT1-STAT1, GAF) to mediate its transcription activity instead of STAT1-STAT2 heterodimer used for IFN-a/b signaling. For this reason, we used IFN-g knockout mice to investigate whether IFN-g plays a role in the protection of Sindbis vector transduction. One day after i.p. Sindbis/Fluc treatment, no liver transduction was observed in IFN-g null mice, except for low levels of transduction in the peritoneal fat ( Figure  1d ), suggesting that the protection of transduction against liver cells is mediated by the IFN-I signaling but not by the IFN-II signaling, even though STAT1 is a shared component for both signaling pathways.
To confirm that adaptive immunity does not contribute to early protection in the liver we studied the transduction kinetics in Stat1 À/À and Stat1
mice. Wild-type 129 Sv/Ev mice were used as control. After Sindbis/Fluc vector i.p. injection, mice were imaged to follow its transduction at different time points ( Figure 2a) . As early as 6 h after transduction, we were able to detect transduction in the lymph nodes (by the neck) and peritoneal fat (lower abdomen) along with lower, but considerable liver transduction signals in both Stat1 À/À and Stat1 À/À Rag2 À/À mice. The bioluminescent signals in the lymph nodes were likely caused by monocyte-dendritic cell transduction. 16 Lymph signals reached highest levels around 12 h after transduction and mostly resolved in 1 day. On the other hand, the signals in liver reach the highest levels 20-25 h after vector treatment and no liver signals were observed after 46 h. Wild-type animals only showed minor transduction in the peritoneal fat that generally resolved within 1 day. A second vector inoculation was given at 118 h (B5 days after the first vector injection) and no significant liver transduction was observed in Stat1
double knockout mice. The lack of retransduction is not likely due to induced adaptive immunity, such as neutralizing antibody, since no liver signal was observed in Stat1 À/À Rag2 À/À mice (Figure 2a and b) . Therefore, in wild-type mice, at early stages of transduction, the vector is suppressed in liver by a STAT1-dependent manner without T or B cells, although a STAT1-independent innate immunity, such as NK cell, may protect mice from second Sindbis/Fluc challenge. 17 Arguing against this possibility is our finding that the absence of NK cells is slightly detrimental to the therapeutic potential of Sindbis vectors in animal tumor models. 10 Sindbis vector transduces non-sinusoidal endothelial cells in the liver of Stat1 À/À mice
Since the liver is a vital organ, it is of interest to determine which cell type in the liver was transduced by Sindbis vector and if the transduction causes any pathological effects to the liver. We performed immunohistology staining of liver sections harvested from Stat1 À/À mice 24 h after transduction by Sindbis/LacZ vector, which expresses a bacterial b-galactosidase. b-gal staining indicated that the vector transduced vascular endothelial cells but not sinusoidal Kupffer cells which are of monocyte lineage (Figure 2c, upper left panel) . In addition, we observed no hepatocyte transduction and no histopathological effects associated with Sindbis transduction in all liver sections examined. Neither necrosis nor inflammation was associated with vector treatment in the liver, consistent with the observation that the treatment caused no morbidity or mortality. This finding is in contrast to the apoptotic and cytopathic effects on tumor cells we have reported previously. 2, 10 As determined by immunohistochemistry (Figure 2c) , vascular endothelial cells express less LAMR than the sinusoidal endothelial cells (Figure 2c ), suggesting that, unlike tumor targeting, the specificity of vector transduction of the vascular endothelial cells is not completely dependent upon higher expression level of LAMR, and other factors may be involved in transduction. One such possibility involves a role for heparan sulfate, which has been shown to mediate Sindbis virus attachment to some mammalian cells.
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STAT1
À/À mice display diminished and delayed IFN-I responses Deficiency of STAT1 should affect the host anti-viral responses in term of IFN-I production. It is known that Figure 1 IFN-I/STAT1 signaling pathway protects mouse liver from Sindbis transduction. Replication-defective Sindbis vectors were produced as described previously 10 and all animal experiments were performed in accordance with NIH and institutional guidelines. (a) 129Sv/Ev wild-type and IFN-a/bR KO mice receive i.p. injection of Sindbis/Fluc vectors (0.5 ml, B10 7 vector particles) on day 0 and day 2. The bioluminescent signals generated by vector transduction were determined using the IVIS Imaging System Series 100 (Xenogen Corp., Alameda, CA, USA) on day 1 and day 3. (c) Immunohistological staining of Stat1 KO liver sections after Sindbis/LacZ transduction. Stat1 KO mice were treated with i.p. injection of Sindbis/LacZ on day 0. Liver tissues were harvested on day 1 and subject to IHC staining using antibodies specific to b-galactosidase (BioDesign International, Kennebunk, ME, USA) or high-affinity laminin receptor (LAMR) (Abcam Ltd., Cambridge, UK). Positive b-gal staining was observed in the non-sinusoidal endothelial cells (indicated by arrows), while higher LAMR staining was observed in the sinusoidal endothelial cells (indicated by arrows). Restricted tissue tropism and acquired resistance to Sindbis viral vector expression J-C Tseng et al mice lacking STAT1 are unable to mount positive feedback amplification and are limited to production of the immediate-early IFN subtype a4 and b when challenged with virus. 20 To verify this, we used enzyme-linked immunosorbent assay (ELISA) assays to determine serum level of IFN-a/b after i.p. Sindbis/Fluc treatments (Figure 3a) . Both Stat1 À/À and Stat1
À/À mice showed diminished and delayed expression of IFN-a/b. In particular, IFN-b, the predominant IFN-I in response to viral infection, was dramatically reduced in mice with STAT1 deficiency. Lack of RAG2 seems to have little impact on the expression of IFN-I. Interestingly, the second challenge of Sindbis/Fluc at 49 h did not evoke a second wave of IFN responses suggesting that the host is still in an anti-viral state. We also checked the levels of tumor necrosis factor (TNF)-a to see if the transduction causes serious inflammation or toxicity. Surprisingly, in contrast to infection of wild-type Sindbis virus in IFN-a/bR knockout mice, 16 very low levels of TNF-a were induced by the transduction of replication defective vector (Figure 3a) .
In addition to reduced and delayed expression levels of IFN-I in sera, the lack of STAT1 should affect the expression of other anti-viral gene products in the liver, which may contribute to establishment of the anti-viral state. We used real-time PCR analysis to determine the expression levels of several genes in the liver (Figure 3b) . Expression of transcription factor IRF7 is reduced and delayed in a manner similar to IFN-a production (Figure 3b) , reflecting the fact that IRF7 can mediate the positive feedback loop of IFN-a expression. 20 On the other hand, IRF3 expression remained unchanged in both wild-type and knockout mice. Other anti-viral genes such as RNA helicase RIG-I, dsRNA protein kinase PKR, dsRNA receptor TLR3, ubiquitin-like modifier ISG15 and ISGylation deconjugating enzyme USP18 genes showed similar reduced and delayed expression patterns in Stat1 À/À liver after Sindbis/Fluc transduction (Figure 3b) . By contrast, expression levels of genes involved in TLR proinflammatory signaling such as p38, IKKa and IKBa showed no difference after transduction (Figure 3b ). In addition, the transcription levels of TNFa did not increase in wild-type or knockout mice. To verify the delayed expression pattern of real-time PCR results, we examined the protein expression levels of IRF3, IRF7 and PKR in wild-type and Stat1 À/À liver (Figure 3c ). Similar to the reverse transcriptase (RT)-PCR result, expression of IRF3 was not affected by Sindbis vector transduction in wild-type and knockout mice. Using a monoclonal antibody as probe, PKR protein expression in the liver was significantly induced by vector transduction in wildtype mice while in the Stat1 À/À liver the induction is delayed and reduced as the RT-PCR result. On the other hand, blotting using a polyclonal antibody capable of detecting multiple phosphorylation forms revealed that, although the expression level increased, PKR was not fully activated in Stat1 À/À liver. Interestingly, the protein levels of IRF7 in wild-type liver increased after vector transduction, as was the case for transcript levels. However, in Stat1 À/À liver, IRF7 protein levels are much lower and no significant expression increases are seen after vector transduction, which is in marked contrast to the expression pattern determined by RT-PCR. The reduced protein level of IRF7 might be due to the translational shut-off mediated by activation of PKR and/or GCN2 resulting phosphorylation of elF2a. 21, 22 In summary, our results indicate that the lack of Stat1, in most case, only delays the expression of anti-viral genes but does not completely prevent their activation. Other alternative mechanisms, such as RIG-I, Mda5 and/or TLR7, might be involved in initiating and establishing an antiviral state in the absence of functional STAT1.
We also used in vivo imaging to investigate if other signaling mechanisms, such as nuclear factor-kappa B (NF-kB), directly participate in the observed protection of liver cells from vector transduction. Classic NF-kB pathways play important roles in cell survival, inflammation and innate immunity. There are three major ways for virus to activate classic NF-kB pathway: TNFa, TLR and PKR. Mice lacking TNF-a receptor (TNFaR) did not show liver transduction after i.p. injections of Sindbis/ Fluc vector (Figure 3d) , which is consistent with the observation that no significant increase in serum TNF-a level after Sindbis vector transduction (Figure 3a) . In addition, mice lacking TLR3 also showed resistance to Sindbis transduction in liver (Figure 3d ). Despite the fact that TLR3 was induced in wild-type liver after Sindbis/ Fluc treatment (Figure 2b ), TLR3 dose not seem to play a role in the early defense of Sindbis vector. Similar negative results were observed in NF-kB (p50) knockout mice (Figure 3d ), suggesting that protection of transduction of liver cells by replication-defective Sindbis vectors does not require TLR-NF-kB inflammatory response. The fact that TLR3 KO mice show no difference in liver protection also indicates that, even if NF-kB is activated, it is not likely via the TNF pathway. However, activation of NF-kB could be achieved by PKR. Although it may not be the case for Stat1 KO mice, since the vector did not induce hyperphosphorylation of PKR for NF-kB activation (Figure 3c ). In conclusion, the classic NF-kB pathway is not likely to be activated by Sindbis vector transduction. Even activated, it may not play an important role of early protection of Sindbis transduction.
These studies demonstrate that even in mice lacking function IFN-I/STAT1 signaling most normal tissues, with the salient exception of the liver, are not susceptible to transduction by Sindbis vectors. The expression of the Sindbis transduced luciferase gene in the liver of knockout mice, but not wild type mice, indicates that IFN-I/ STAT1 signaling protects mice from the initial Sindbis vector transduction of liver cells. This liver transduction is limited to the non-sinusoidal endothelium cells. Several IFN-responsive genes were activated in Stat1 knockout mice after the initial Sindbis vector transduction, although at a slower rate than in wild-type animals. However, after the initial transduction other antiviral mechanism must be responsible for control of vector transduction, since subsequent Sindbis vector injections in IFNAR or STAT1 knockout mice fail to transduce liver cells. Despite susceptibility in the knockout mice, no adverse effects from the initial or subsequent injections were observed.
Several factors might contribute to the acquired resistance to Sindbis transduction we observed in mouse liver. One simple explanation is that the vector transduces and eliminates the initial transduced sinusoidal endothelial cells, although no noticeable tissue damage and inflammation is observed in liver tissue section after transduction. Liver regeneration is rapid and would argue that this type of protection would not be long- (Figure 3 ). IRF3 has been shown to mediate IFN-independent antiviral responses in cell culture and its activation does not require replication active virus. 23 An IRF3-dependent antiviral mechanism would likely be cell autonomous in the absence of IFN signaling. For this to be the mechanism mediating Sindbis resistance in vivo, only cells transduced from the first inoculum would be protected from subsequent challenge. Although we doubt that our initial transduction efficiently targets all cells that could be subsequently permissive, this notion will require further investigation. On the other hand, activation of such mechanism may need help from other immune cell types, such as NK cells or monocyte linage. More studies are required to elucidate the mechanism behind the acquired resistance.
In the present studies, our imaging data provide evidences, for the first time, suggesting the existence of IFN/STAT1-independent antiviral mechanism(s) in live animals. IFN-I/STAT1 signaling plays an important role in the initial protection of non-sinusoidal endothelial cells in blood vessels of the mouse liver from Sindbis viral vector transduction, but probably plays no role in protection of other normal cells. In addition, the facts that the initial liver transductions are self-limited, and the vector causes no observable morbidity or mortality even after repetitive injection in animals lacking functional IFN/STAT1 signaling, increase the likelihood that replication-defective Sindbis vectors may be able to show therapeutic benefits.
Unlike the IFN responses triggered in some normal cells that protect the host from unwanted toxicity after Sindbis vector treatment, the IFN responses raised in tumor cells would be expected to reduce the vectors' therapeutic efficacy. However, it has been shown that some cancer cells acquire genetic defects during tumorigenesis to diminish IFN responses, [24] [25] [26] [27] [28] suggesting that IFN signaling pathways may regulate cell growth and mediate apoptosis in addition to providing innate immunity against viral infection. Some viral vector systems, such as one based on vesicular stomatitis virus (VSV), have been genetically engineered for selective replication and lysis in tumor cells that lack functional IFN responses. 29, 30 In the case of replication-defective Sindbis vector, it is still not clear whether IFN responsiveness plays any role in specific tumor targeting. Any innate immunity in transduced tumors may suppress the replication of viral vectors and reduce their therapeutic efficacy against cancer cells. The flip side is that, if cancer cells downregulate IFN-I responses to obtain growth advantage, Sindbis vectors, like VSV vectors, may gain increased tumor targeting specificity. Such specificity would build on the exquisite tumor targeting resulting from differential unoccupied LAMR expression between normal and tumor cells. Normal cells would be expected to retain their IFN responsiveness and resist viral replication, whereas tumor cells, defective in IFNmediated responses, would more readily support viral replication.
